This region consists of 45 countries and is the number one region in the Commercial Pharmaceuticals segment by revenue, mainly driven by South Africa. Across the multiple countries in the region, commercial and sales employees not only support well-established local brands, but also internationally recognised medicines, with both having strong brand equity attributes. The primary manufacturing site in the region is in Gqeberha, South Africa, which has manufacturing capabilities extending to steriles and biologicals that are extensive, niche and differentiated including high potency and hormonal solids, as well as vaccines and other state-of-the-art sterile
capabilities. There are two further regional manufacturing sites in South Africa which are located in Cape Town and East London. Additional regional sites in Africa are in Ghana, Kenya and Tanzania.

Latin America continues to dominate this region, with Mexico and Brazil being the most significant contributors to the region’s performance. There is one manufacturing site in this region which is situated in Brazil and which focuses on finished dose form (“FDF”). The region commercialises internationally recognised medicines across the prescription, hospital and over-the-counter (“OTC”) channels.

The region is the largest contributor to the Group’s Sterile Focus Brands revenue and comprises all Asian territories including China. Active trading subsidiaries include those in China, the Philippines, Taiwan, and Malaysia with other countries and territories in the region such as Hong Kong reached via distributors. The region has one manufacturing site in Hyderabad, India, which is focused on new product development.

After Africa, Aspen Australasia is the second largest revenue contributor to Regional Brands, with a comprehensive portfolio of medicines comprising Regional and Global Brands, including prescription and OTC products, as well as Sterile Focus Brands. There is also a manufacturing site in Australia, which produces FDF and undertakes third-party manufacturing.

Europe CIS provides a broad range of Sterile Focus and Regional Brands and undertakes third-party manufacturing. The revenue contribution from the Sterile Focus Brands portfolio is the second highest after Asia, and consists of Anaesthetics and to a lesser extent Thrombosis products in Russia and the Europe CIS region. The manufacturing operations, which span across both active pharmaceutical ingredients (“APIs”) and FDF production, are widely accredited and provide a variety of technologies for Aspen’s own commercialisation strategy and for third-party use.